The  ||| S:0 E:4 ||| DT
immunology  ||| S:4 E:15 ||| NN
of  ||| S:15 E:18 ||| IN
ankylosing  ||| S:18 E:29 ||| JJ
spondylitis  ||| S:29 E:41 ||| NN
and  ||| S:41 E:45 ||| CC
rheumatoid  ||| S:45 E:56 ||| JJ
arthritis ||| S:56 E:65 ||| NN
:  ||| S:65 E:67 ||| :
a  ||| S:67 E:69 ||| DT
tale  ||| S:69 E:74 ||| NN
of  ||| S:74 E:77 ||| IN
similarities  ||| S:77 E:90 ||| NNS
and  ||| S:90 E:94 ||| CC
dissimilarities  ||| S:94 E:110 ||| FW
Ankylosing  ||| S:110 E:121 ||| FW
spondylitis  ||| S:121 E:133 ||| FW
( ||| S:133 E:134 ||| -LRB-
AS ||| S:134 E:136 ||| NNP
)  ||| S:136 E:138 ||| -RRB-
and  ||| S:138 E:142 ||| CC
rheumatoid  ||| S:142 E:153 ||| JJ
arthritis  ||| S:153 E:163 ||| NN
( ||| S:163 E:164 ||| -LRB-
RA ||| S:164 E:166 ||| NNP
)  ||| S:166 E:168 ||| -RRB-
are  ||| S:168 E:172 ||| VBP
immune-mediated  ||| S:172 E:188 ||| JJ
inflammatory  ||| S:188 E:201 ||| JJ
joint  ||| S:201 E:207 ||| JJ
diseases  ||| S:207 E:216 ||| NNS
with  ||| S:216 E:221 ||| IN
the  ||| S:221 E:225 ||| DT
potential  ||| S:225 E:235 ||| NN
for  ||| S:235 E:239 ||| IN
significant  ||| S:239 E:251 ||| JJ
target  ||| S:251 E:258 ||| NN
organ  ||| S:258 E:264 ||| NN
damage ||| S:264 E:270 ||| NN
.  ||| S:270 E:272 ||| .
Genetic  ||| S:272 E:280 ||| JJ
factors  ||| S:280 E:288 ||| NNS
play  ||| S:288 E:293 ||| VBP
an  ||| S:293 E:296 ||| DT
important  ||| S:296 E:306 ||| JJ
role  ||| S:306 E:311 ||| NN
in  ||| S:311 E:314 ||| IN
defining  ||| S:314 E:323 ||| JJ
disease  ||| S:323 E:331 ||| NN
susceptibility ||| S:331 E:345 ||| NN
.  ||| S:345 E:347 ||| .
Both  ||| S:347 E:352 ||| DT
diseases  ||| S:352 E:361 ||| NNS
are  ||| S:361 E:365 ||| VBP
mediated  ||| S:365 E:374 ||| VBN
in  ||| S:374 E:377 ||| IN
part  ||| S:377 E:382 ||| NN
by  ||| S:382 E:385 ||| IN
TNF ||| S:385 E:388 ||| NNP
,  ||| S:388 E:390 ||| ,
since  ||| S:390 E:396 ||| IN
anti-TNF  ||| S:396 E:405 ||| JJ
therapies  ||| S:405 E:415 ||| NNS
have  ||| S:415 E:420 ||| VBP
proved  ||| S:420 E:427 ||| VBN
effective  ||| S:427 E:437 ||| JJ
in  ||| S:437 E:440 ||| IN
both  ||| S:440 E:445 ||| DT
AS  ||| S:445 E:448 ||| NNP
and  ||| S:448 E:452 ||| CC
RA ||| S:452 E:454 ||| NNP
.  ||| S:454 E:456 ||| .
Despite  ||| S:456 E:464 ||| IN
their  ||| S:464 E:470 ||| PRP$
similarities ||| S:470 E:482 ||| NNS
,  ||| S:482 E:484 ||| ,
the  ||| S:484 E:488 ||| DT
genetic  ||| S:488 E:496 ||| JJ
elements  ||| S:496 E:505 ||| NNS
associated  ||| S:505 E:516 ||| VBN
with  ||| S:516 E:521 ||| IN
the  ||| S:521 E:525 ||| DT
respective  ||| S:525 E:536 ||| JJ
diseases  ||| S:536 E:545 ||| NNS
differ ||| S:545 E:551 ||| VBP
,  ||| S:551 E:553 ||| ,
most  ||| S:553 E:558 ||| RBS
notably  ||| S:558 E:566 ||| RB
in  ||| S:566 E:569 ||| IN
HLA  ||| S:569 E:573 ||| NNP
associations ||| S:573 E:585 ||| NNS
,  ||| S:585 E:587 ||| ,
with  ||| S:587 E:592 ||| IN
AS  ||| S:592 E:595 ||| IN
being  ||| S:595 E:601 ||| VBG
associated  ||| S:601 E:612 ||| VBN
with  ||| S:612 E:617 ||| IN
class  ||| S:617 E:623 ||| NN
I  ||| S:623 E:625 ||| PRP
HLA  ||| S:625 E:629 ||| VBP
alleles  ||| S:629 E:637 ||| VBN
and  ||| S:637 E:641 ||| CC
RA  ||| S:641 E:644 ||| NNP
associated  ||| S:644 E:655 ||| VBN
with  ||| S:655 E:660 ||| IN
class  ||| S:660 E:666 ||| NN
II  ||| S:666 E:669 ||| NNP
HLA  ||| S:669 E:673 ||| NNP
alleles ||| S:673 E:680 ||| NN
.  ||| S:680 E:682 ||| .
AS  ||| S:682 E:685 ||| RB
has  ||| S:685 E:689 ||| VBZ
a  ||| S:689 E:691 ||| DT
predilection  ||| S:691 E:704 ||| NN
for  ||| S:704 E:708 ||| IN
axial  ||| S:708 E:714 ||| JJ
joints  ||| S:714 E:721 ||| NNS
whereas  ||| S:721 E:729 ||| IN
RA  ||| S:729 E:732 ||| NNP
targets  ||| S:732 E:740 ||| VBZ
peripheral  ||| S:740 E:751 ||| JJ
joints ||| S:751 E:757 ||| NNS
,  ||| S:757 E:759 ||| ,
but  ||| S:759 E:763 ||| CC
the  ||| S:763 E:767 ||| DT
immunological  ||| S:767 E:781 ||| JJ
basis  ||| S:781 E:787 ||| NN
of  ||| S:787 E:790 ||| IN
that  ||| S:790 E:795 ||| DT
distinction  ||| S:795 E:807 ||| NN
is  ||| S:807 E:810 ||| VBZ
unknown ||| S:810 E:817 ||| JJ
.  ||| S:817 E:819 ||| .
Autoantibody  ||| S:819 E:832 ||| JJ
formation  ||| S:832 E:842 ||| NN
is  ||| S:842 E:845 ||| VBZ
the  ||| S:845 E:849 ||| DT
immunological  ||| S:849 E:863 ||| JJ
hallmark  ||| S:863 E:872 ||| NN
of  ||| S:872 E:875 ||| IN
RA ||| S:875 E:877 ||| NNP
,  ||| S:877 E:879 ||| ,
whereas  ||| S:879 E:887 ||| IN
AS  ||| S:887 E:890 ||| NNP
is  ||| S:890 E:893 ||| VBZ
notable  ||| S:893 E:901 ||| VBN
for  ||| S:901 E:905 ||| IN
being  ||| S:905 E:911 ||| VBG
a  ||| S:911 E:913 ||| DT
seronegative  ||| S:913 E:926 ||| JJ
disease ||| S:926 E:933 ||| NN
.  ||| S:933 E:935 ||| .
Growing  ||| S:935 E:943 ||| VBG
knowledge  ||| S:943 E:953 ||| NN
of  ||| S:953 E:956 ||| IN
new  ||| S:956 E:960 ||| JJ
aspects  ||| S:960 E:968 ||| NNS
of  ||| S:968 E:971 ||| IN
the  ||| S:971 E:975 ||| DT
host  ||| S:975 E:980 ||| NN
immune  ||| S:980 E:987 ||| JJ
response  ||| S:987 E:996 ||| NN
( ||| S:996 E:997 ||| -LRB-
such  ||| S:997 E:1002 ||| JJ
as  ||| S:1002 E:1005 ||| IN
innate  ||| S:1005 E:1012 ||| JJ
immune  ||| S:1012 E:1019 ||| JJ
responses  ||| S:1019 E:1029 ||| NNS
and  ||| S:1029 E:1033 ||| CC
Th17  ||| S:1033 E:1038 ||| CD
cells ||| S:1038 E:1043 ||| NNS
)  ||| S:1043 E:1045 ||| -RRB-
is  ||| S:1045 E:1048 ||| VBZ
adding  ||| S:1048 E:1055 ||| VBG
to  ||| S:1055 E:1058 ||| TO
new  ||| S:1058 E:1062 ||| JJ
insights  ||| S:1062 E:1071 ||| NNS
into  ||| S:1071 E:1076 ||| IN
shared  ||| S:1076 E:1083 ||| JJ
mechanisms  ||| S:1083 E:1094 ||| NNS
of  ||| S:1094 E:1097 ||| IN
pathogenesis  ||| S:1097 E:1110 ||| NN
between  ||| S:1110 E:1118 ||| IN
these  ||| S:1118 E:1124 ||| DT
two  ||| S:1124 E:1128 ||| CD
diseases ||| S:1128 E:1136 ||| NNS
.  ||| S:1136 E:1138 ||| .
